<code id='52C50E53CD'></code><style id='52C50E53CD'></style>
      • <acronym id='52C50E53CD'></acronym>
      <center id='52C50E53CD'><center id='52C50E53CD'><tfoot id='52C50E53CD'></tfoot></center><abbr id='52C50E53CD'><dir id='52C50E53CD'><tfoot id='52C50E53CD'></tfoot><noframes id='52C50E53CD'>
      • <optgroup id='52C50E53CD'><strike id='52C50E53CD'><sup id='52C50E53CD'></sup></strike><code id='52C50E53CD'></code></optgroup>
        5. <b id='52C50E53CD'><label id='52C50E53CD'><select id='52C50E53CD'><dt id='52C50E53CD'><span id='52C50E53CD'></span></dt></select></label></b><u id='52C50E53CD'></u>
          <i id='52C50E53CD'><strike id='52C50E53CD'><tt id='52C50E53CD'><pre id='52C50E53CD'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-09-28 02:53:25 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：8292
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          AstraZeneca CEO says participant had neurological symptoms, could be discharged today
                                
                            
          Next article：  
                                      
                                          The cancer drug shortage isn’t new — and neither are the solutions
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles